Arseus experienced a successful 2007. Enormous progress has been made since the 2006 decision to spin off Omega Pharma’s B2B divisions as a private company. Not only in turnover and profi t, but also in terms of sales and marketing, IT, business development and especially backoffice optimisation. In 2007, for example, virtually all Belgium-based commercial and logistical services were centralised in Waregem.

Arseus growth in 2007:
Fagron + 14%
Arseus Dental + 10%
Arseus Medical + 5%
Corilus + 5%
Total Arseus + 10%

On 5 October 2007 the Arseus share was listed in Brussels and Amsterdam at €10.25. A very successful IPO was closed out in three months. Our priority since then has been the interests of our shareholders. The management of Arseus also has a large shareholding in the Company.

Italy’s Polichimica was acquired as part of the buy and build strategy. The Bologna-based enterprise was incorporated into Fagron Group, bolstering its geographical expansion. As a member of Fagron Group, Polichimica will be in a position to profi t from synergies with other countries.

In 2007 Arseus Dental concentrated on integrating Eurotec and Besserat, two acquisitions from 2006, and expanding the equipment and dental labs distribution network in France and Germany. In 2007 Arseus Dental laid solid foundations on which to build.

Arseus Medical focused on the internal organisation and improving profi tability in 2007, backed by numerous back-offi ce initiatives.

In 2007 Corilus was transformed into a welloiled sales and marketing machine, with a focus on improving the balance of the product mix, from hardware to software.

The management of Arseus is sure that the advancements made in 2007 constitute a healthy foundation for a prosperous future.